Cargando…
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
BACKGROUND: Toripalimab is a humanized immunoglobulin G(4) monoclonal antibody against programmed death 1. We aimed to investigate the efficacy and safety of toripalimab in combination with intensity-modulated radiotherapy (IMRT) for recurrent nasopharyngeal carcinoma (rNPC). METHODS: We conducted a...
Autores principales: | Hua, Yijun, You, Rui, Wang, Zhiqiang, Huang, Peiyu, Lin, Mei, Ouyang, Yanfeng, Xie, Yulong, Zou, Xiong, Liu, Youping, Duan, Chongyang, Liu, Yonglong, Gu, Chenmei, Liu, Rongzeng, Yang, Qi, Jiang, Rou, Zhang, Mengxia, Ding, Xi, Chen, Siyuan, Lin, Chao, Sun, Rui, Chen, Mingyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593727/ https://www.ncbi.nlm.nih.gov/pubmed/34782428 http://dx.doi.org/10.1136/jitc-2021-003290 |
Ejemplares similares
-
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022) -
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021) -
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial
por: Chen, Si-Yuan, et al.
Publicado: (2023) -
Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020) -
Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment
por: Wang, Xiwei, et al.
Publicado: (2022)